Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Suspected vaccination failure; recently developed shingles; This serious case was reported by a nurse via sales rep and described the occurrence of vaccination failure in a 70-year-old female patient who received Herpes zoster (Shingrix) for an unknown indication. Co-suspect products included mepolizumab (Nucala) for product used for unknown indication. On an unknown date, the patient received Shingrix and Nucala. On an unknown date, an unknown time after receiving Shingrix and not applicable after starting Nucala, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: recently developed shingles). The action taken with Nucala was unknown. The outcome of the vaccination failure was unknown and the outcome of the shingles was resolved. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix. It was unknown if the reporter considered the shingles to be related to Nucala. The company considered the vaccination failure to be unrelated to Shingrix and Nucala. It was unknown if the company considered the shingles to be related to Shingrix and Nucala. Additional Information: GSK Receipt Date: 16-FEB-2026 A patient had the Shingle vaccination and had been on Nucala. She recently developed shingles and was hesitant to continue with Nucala due to fear of shingles returning. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: A case of Vaccination failure, unknown time after receiving Shingrix and not applicable after starting Nucala, in a 70-year-old female patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Further follow up information has been sought.
Nucala